PT - JOURNAL ARTICLE AU - ter Maat, L.S. AU - van Duin, I.A.J. AU - Elias, S.G. AU - Leiner, T. AU - Verhoeff, J.J.C. AU - Arntz, E.R.A.N. AU - Troenokarso, M.F. AU - Blokx, W.A.M. AU - Isgum, I. AU - de Wit, G.A. AU - van den Berkmortel, F.W.P.J. AU - Boers-Sonderen, M.J. AU - Boomsma, M.F. AU - van den Eertwegh, A.J.M. AU - de Groot, J.W.B. AU - Piersma, D. AU - Vreugdenhil, G. AU - Westgeest, H.M AU - Kapiteijn, E. AU - van Diest, P.J. AU - Pluim, J.P.W. AU - de Jong, P.A. AU - Suijkerbuijk, K.P.M. AU - Veta, M. TI - CT radiomics to predict checkpoint inhibitors treatment outcomes in patients with advanced cutaneous melanoma AID - 10.1101/2022.12.19.22283574 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.19.22283574 4099 - http://medrxiv.org/content/early/2022/12/20/2022.12.19.22283574.short 4100 - http://medrxiv.org/content/early/2022/12/20/2022.12.19.22283574.full AB - Introduction Predicting checkpoint inhibitors treatment outcomes in melanoma is a relevant task, due to the unpredictable and potentially fatal toxicity and high costs for society. However, accurate biomarkers for treatment outcomes are lacking. Radiomics are a technique to quantitatively capture tumor characteristics on readily available computed tomography (CT) imaging. The purpose of this study was to investigate the added value of radiomics for predicting durable clinical benefit from checkpoint inhibitors in melanoma in a large, multicenter cohort.Methods Patients who received first-line anti-PD1 ± anti-CTLA4 treatment for advanced cutaneous melanoma were retrospectively identified from nine participating hospitals. For every patient, up to five representative lesions were segmented on baseline CT and radiomics features were extracted. A machine learning pipeline was trained on the radiomics features to predict durable clinical benefit, defined as stable disease for more than six months or response per RECIST 1.1 criteria. This approach was evaluated using a leave-one-center-out cross validation and compared to a model based on previously discovered clinical predictors. Lastly, a combination model was built on the radiomics and clinical model.Results A total of 620 patients were included, of which 59.2% experienced durable clinical benefit. The radiomics model achieved an area under the receiver operator characteristic curve (AUROC) of 0.607 [95%CI 0.562-0.652], lower than that of the clinical model (AUROC=0.646 [95%CI 0.600-0.692]). The combination model yielded no improvement over the clinical model in terms of discrimination (AUROC=0.636 [95%CI 0.592-0.680]) or calibration. The output of the radiomics model was significantly correlated with three out of five input variables of the clinical model (p < 0.001).Discussion The radiomics model achieved a moderate predictive value of durable clinical benefit, which was statistically significant. However, a radiomics approach was unable to add value to a simpler clinical model, most likely due to the overlap in predictive information learned by both models. Future research should focus on the application of deep learning, spectral CT derived radiomics and a multimodal approach for accurately predicting benefit to checkpoint inhibitor treatment in advanced melanoma.Competing Interest StatementAvdE has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis. JdG has consultancy/advisory relationships with Bristol Myers Squibb, Pierre Fabre, Servier, MSD, Novartis. PJ has a research collaboration with Philips Healthcare and Vifor Pharma. MBS has consultancy/advisory relationships with Pierre Fabre, MSD and Novartis. EK has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, Lilly, Bayer, EISAI and Ipsen, and received research grants not related to this paper from Bristol Myers Squibb and Pierre Fabre. PD has consultancy/advisory relationships with Paige, Pantarei and Samantree paid to the institution and research grants from Pfizer, none related to current work and paid to institute. KS has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, AbbVie and received honoraria from Novartis, MSD and Roche and research funding from Bristol Myers Squibb, TigaTx and Philips. TL has received research funding from Philips. All remaining authors have declared no conflicts of interest. Funding StatementThis research was funded by The Netherlands Organization for Health Research and Development (ZonMW, project number 848101007) and Philips.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics Committee of the University Medical Center Utrecht waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A